(Q33407582)

English

Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

11

object named as

Sofia Agelaki

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Athanasios Karampeazis

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Alexandra Voutsina

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

John Souglakos

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Nikos Kentepozidis

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Stelios Giassas

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Charalambos Christofillakis

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Athanasios Kotsakis

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Pavlos Papakotoulas

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ageliki Rapti

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Maria Agelidou

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lambros Vamvakas

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

George Samonis

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimitris Mavroudis

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Vassilis Georgoulias

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

9 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

119

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2754-2764

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

FDA drug approval summary: erlotinib (Tarceva) tablets

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28132

21 January 2018

Identifiers

10.1002/CNCR.28132

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33407582&oldid=1954135800"